Table 31

Summary of study characteristics for RCTs of long-acting risperidone versus placebo or oral risperidone.

Intramuscular injection of long- acting risperidone vs. placebo injectionIntramuscular injection of long- acting risperidone vs. oral risperidone + placebo injection
k (total N)1 (400)1 (642)
Study IDKANE2003CHUE2005
Diagnostic criteriaSchizophrenia (DSM-IV)Schizophrenia (DSM-IV)
Baseline severity25 mg long-acting risperidone: PANSS total: mean 81.7 (SD 12.5), n = 99
50 mg long-acting risperidone: PANSS total: mean 82.3 (SD 13.9), n = 103
75 mg long-acting risperidone: PANSS total: mean 80.1 (SD 14.0), n = 100
Placebo: PANSS total: mean 82.0 (SD 14.4), n = 98
Long-acting risperidone: PANSS total: mean 68.4 (SD 1.0), n = 319
Oral risperidone: PANSS total: mean 69.3(SD 0.9), n = 321

Note. All participants were required to be symptomatically stable during the last 4 weeks of the run-in period
Run-in1-week oral risperidone run-in period8 weeks open-label period during which participants were stabilized on oral risperidone
SettingInpatient/outpatientInpatient/outpatient
Duration of treatment12 weeks12 weeks
Medication dose (mg/day)Fixed dose of 25, 50 or 75 mg every 2 weeksLong-acting risperidone: 88 participants received 25 mg every 2 weeks, 126 received 50 mg and 105 received 75 mg

Oral risperidone: 86 participants received 2 mg/day, 126 received 4 mg/day and 109 received 6 mg/day

From: 6, Pharmacological interventions in the treatment and management of schizophrenia

Cover of Schizophrenia
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet].
NICE Clinical Guidelines, No. 82.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009 Mar.
Copyright © 2009, National Collaborating Centre for Mental Health.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.